CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-08-04). The draft was written by AI, the existence of all 2 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 2238 · Search date 2026-08-04 · Methodology v0.6

High-dose infant vitamin D,
does it really help with Greater bone strength at 24 months than standard 400 IU daily?

30-Second Summary
D
Evidence Grade D · 36 · Safety caution
In healthy term infants, 1,200 IU raised blood levels over 400 IU but did not improve bone measures
No major between-group safety difference was established at the trial doses, but duplicate products and excessive infant dosing should be avoided. Clinicians should set doses for infants with deficiency or disease.
What the
research shows
The grade is D. Finland's VIDI trial randomized 975 healthy term infants to 400 or 1,200 IU daily. At 24 months, peripheral quantitative computed tomography found a bone-mineral-content difference of 0.4 mg/mm (95% CI -0.8 to 1.6) and a density difference of 2.9 mg/cm3 (-8.3 to 14.2), with no added benefit.
What the
ads claim
A higher blood concentration does not mean stronger bone. This trial specifically tested additional benefit above standard supplementation.
*

Useful facts when choosing a product

  • At 24 months, 25(OH)D was 12.50 ng/mL higher in the 1,200-IU group.
  • Adjusted differences were 0.4 mg/mm for total-bone mineral content and 2.9 mg/cm3 for density.
  • Bone was measured by peripheral quantitative computed tomography, and 79 scans with motion artifact were excluded.
Gap Measurement · Verdict 2238 · D 36
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

From age two weeks to 24 months, 489 infants received 400 IU daily and 486 received 1,200 IU. Eight hundred twenty-three (84.4%) completed the 24-month visit. Of 783 pQCT scans, 79 with motion artifact were excluded, leaving 704 in bone analysis; the paper described analysis by the intention-to-treat principle. Loss to follow-up exceeded 15%. The investigator-initiated trial stated independence, while Orion Pharmaceuticals prepared the supplements.

02

Why this is classified as D (36)

All registered bone primary outcomes in a large prospectively registered trial were null, giving D with 36 points; the sample-size assumption of 0.2 SD was not promoted to a refutation threshold.

Counterpoint. A confidence interval crossing zero does not itself exclude meaningful benefit. These results do not apply to deficient infants, preterm infants, or rickets treatment.

Rejudgment record. Cross-check applied — Null 24-month pQCT bone primary outcomes in a prospectively registered 975-infant trial without exclusion of clinically meaningful benefit

Scoring profile behind this grade
EndpointSSurrogate marker - laboratory or imaging measures
ReplicationR1Single confirmatory trial
IndependenceI2Decisive evidence is publicly or non-profit funded
Effect sizeE0Null
PrecisionC0The confidence interval leaves room for benefit

The scoring table and the verdict agree (D).

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Greater bone strength than standard doseDAll registered pQCT bone outcomes were null.
Higher serum 25(OH)DCIt was 12.50 ng/mL higher, but this is not a bone-efficacy outcome.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Study 1Double-blind randomized dose-comparison trial704Finnish public and foundation funding; Orion prepared supplements; investigator-initiated independent trial24-month pQCT bone mineral content, density, cross-sectional area, and polar moment of inertiaBone-mineral-content difference 0.4 mg/mm (95% CI -0.8 to 1.6); density 2.9 mg/cm3 (-8.3 to 14.2)Definitive large null evidence
§

Receipt — 2 References

All 2 cited sources were verified for existence at the original page (as of 2026-08-04).

Rosendahl J, Valkama S, Holmlund-Suila E, et al. Effect of Higher vs Standard Dosage of Vitamin D3 Supplementation on Bone Strength and Infection in Healthy Infants: A Randomized Clinical Trial. JAMA Pediatr. 2018;172(7):646-654. PMID: 29813149.
checked
Helve O, Viljakainen H, Holmlund-Suila E, et al. Towards evidence-based vitamin D supplementation in infants: VIDI study design and methods. BMC Pediatr. 2017;17:91. PMID: 28356142. DOI: 10.1186/s12887-017-0845-5.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-08-04 · Corrections: none

Cite this verdict

High-dose infant vitamin D x additional bone-strength benefit over standard dose Evidence Grade D card
[Chamgap] High-dose infant vitamin D x additional bone-strength benefit over standard dose — Evidence Grade D·36. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/joint-bone/high-dose-vitamin-d-infant-bone-strength/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.